98%
921
2 minutes
20
Objective: The use of autologous bone for cranioplasty offers superior cosmesis and cost-effectiveness compared with synthetic materials. The choice between 2 common autograft storage mechanisms (subcutaneous vs. frozen) remains controversial and dictated by surgeon preference. We compared surgical outcomes after autologous bone cranioplasty between patients with cryopreserved and subcutaneously stored autografts.
Methods: Ten-year retrospective comparative analysis of patients undergoing cranioplasty with autologous bone stored subcutaneously or frozen at a tertiary academic medical center.
Results: Ninety-four patients were studied, with 34 (36.2%) bone flaps stored subcutaneously and 59 (62.8%) frozen. The 2 groups were similar in demographics, comorbidities, and craniectomy indication, with only body mass index and race differing statistically. The mean operation time was greater within the subcutaneous group (P < 0.001), which also had a greater number of ventriculoperitoneal shunt (VPS) placements (P = 0.02). There were no significant differences in complications, readmissions, unplanned reoperations, or length of stay between the 2 groups. VPS placement during cranioplasty increased length of stay (P < 0.001), and placement prior to cranioplasty increased both length of stay (P = 0.009) and incidence of hospital-acquired infection (P = 0.03).
Conclusions: Subcutaneous and frozen storage of autologous bone result in similar surgical risk profiles. Cryopreservation may be preferred because of shorter operation time and avoidance of complications with the abdominal pocket, whereas the portability of subcutaneous storage remains favorable for patients undergoing cranioplasty at a different institution. VPS placement prior to cranioplasty should be avoided, if possible, due to the increased risk of hospital-acquired infection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2019.07.139 | DOI Listing |
Blood Neoplasia
November 2025
Section of Hematology/Oncology, The University of Chicago, Chicago, IL.
Modern multiple myeloma treatment enables deep and sustained responses, necessitating assessment of minimal residual disease (MRD) in the bone marrow to refine response categorization. Recently, mass spectrometry (MS)-based methods have emerged as highly sensitive tools for measuring MRD in the peripheral blood. However, the role specific MS techniques play in response categorization has yet to be established.
View Article and Find Full Text PDFCureus
August 2025
Dental and Oral Medical Center, Kurume University School of Medicine, Kurume, JPN.
Functional reconstruction of large mandibular defects, especially in young patients, presents a significant clinical challenge. The ideal approach should not only restore skeletal contour but also address nerve deficits and facilitate final occlusal rehabilitation, all while minimizing morbidity. This report describes a comprehensive, multi-staged strategy for such a case.
View Article and Find Full Text PDFCureus
August 2025
Orthopedics, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Giant cell tumor (GCT) of the bone, although benign, demonstrates local aggressiveness, a potential for recurrence, and, in rare instances, malignant transformation. Functional preservation is crucial in cases involving the articular surface, often utilizing the Sandwich Technique. We propose an enhanced reconstruction method using the inner table of the iliac crest in a reverse fashion, offering a more anatomically contoured proximal tibial plateau and reducing donor site morbidity compared to tricortical iliac crest grafting.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
September 2025
Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
X-linked agammaglobulinemia (XLA) is a rare inborn error of immunity caused by loss-of-function mutations in the gene encoding Bruton's tyrosine kinase (BTK). XLA patients lack mature B cells and have negligible antibody levels, leaving them susceptible to recurrent bacterial and chronic viral infections. Autologous hematopoietic stem cell gene therapy with gene-corrected HSC may serve as a promising treatment of XLA; this therapy would provide a one-time cure and would replace lifelong immunoglobulin replacement therapy.
View Article and Find Full Text PDFRSC Adv
August 2025
Department of Bioengineering and iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa Av. Rovisco Pais Lisboa 1049-001 Portugal
Bone-related injuries represent a major global challenge, particularly for the aging population. While bone has self-healing capabilities, large defects and non-union fractures often fail to completely regenerate, leading to long-term disability and the need for surgical intervention. Autologous bone grafts remain the gold standard for such procedures, but challenges such as limited donor availability and donor site comorbidity persist.
View Article and Find Full Text PDF